Tg197 transgenic mice: a unique model of human arthritis pathology

Tg197 is a transgenic mouse overexpressing human TNF resulting in the spontaneous development of arthritis pathology closely resembling human rheumatoid arthritis. The mice develop arthritis with 100% penetrance and provide a fast in-vivo model for the evaluation of human therapeutics targeting rheumatoid arthritis.

Target:

Arthritis

Date:

March 20, 2024

Category:

The Tg197 mouse model was successfully used in establishing the therapeutic efficacy of Remicade®, the first anti-TNF therapeutic to be successfully applied in the clinic, and has since be used extensively for the FDA approval of many anti-rheumatoid candidate drugs.

Model Description

Tg197 mice develop spontaneous arthritis characterized by ankle swelling, hind limb distortion, impaired movement and progressive weight loss. With symptoms first becoming apparent at 3-4 weeks of age, the disease becomes established at 6-7 weeks of age and progressively worsens with age. Animals left untreated exhibit increased morbidity by 11-12 weeks of age.

Arthritic Score and Body Weight

Tg197 mice exhibit progressive worsening arthritis and reduced body weight gain due to the human TNF overexpression that causes cachexia

Circulating Cytokine Levels

Tg197 mice exhibit increased levels of serum circulating human TNF and mouse IL-6

Preclinical Platform

Treatment can start either at 3 weeks of age, at the onset of pathology (prophylactic protocol), or at 6 weeks of age, at the stage of established pathology (therapeutic protocol)

Enhance Your Research Strategy Today

Partner with Our Skilled Scientists and discover Cutting-Edge Solutions!
Contact Us